Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02790437 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test
A Phase 2 study of Kidney Failure, Chronic, sponsored by Hansa Biopharma AB.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 5
- Study locations
NCT02790437 is a Phase 2 study of Kidney Failure, Chronic that has completed, run by Hansa Biopharma AB. The registered enrollment target is 19 participants, below the 331-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT02790437, a Phase 2 study of Kidney Failure, Chronic, has completed, sponsored by Hansa Biopharma AB.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness of the study drug IdeS in patients who are on the waiting list for kidney transplant and have previously undergone desensitization unsuccessfully or in whom effective desensitization will be highly unlikely. At study entry, the patients will have an available deceased or live donor with a positive crossmatch test. The study will assess IdeS efficacy and safety in removing Donor Specific Antibodies (DSAs) and thereby convert a positive crossmatch test to negative.
Conditions Studied
Interventions
- DRUG IdeS
- PROCEDURE Kidney transplantation
Study Locations (5)
Other
- Necker Hospital - Paris
- Uppsala University Hospital - Uppsala
California
- Cedars-Sinai Medical Center - Los Angeles
Maryland
- The Johns Hopkins Hospital - Baltimore
New York
- New York University School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02790437
The ClinicalTrials.gov registry entry for NCT02790437 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 331-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (94% lower). The listed sponsor is Hansa Biopharma AB, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 2 interventions - of which IdeS is the first listed.
NCT02790437 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT02790437 about?
NCT02790437 is a clinical study titled "A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test". The purpose of this study is to evaluate the effectiveness of the study drug IdeS in patients who are on the waiting list for kidney transplant and have previously undergone desensitization unsuccessfully or in whom effective desensitization will be highly unlikely. At study entry, the patients will...
What is the current status of trial NCT02790437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2016-06. Estimated completion is 2018-07-03.
What conditions does trial NCT02790437 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic.
What interventions are being tested in trial NCT02790437?
The interventions under investigation include: IdeS (DRUG), Kidney transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT02790437?
This trial is sponsored by Hansa Biopharma AB, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02790437 being conducted?
This trial has 5 study locations across California, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DePTH: De-emphasize PTH
ACTIVE NOT RECRUITING · Phase 2
-
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
COMPLETED · Phase 2
-
Exercise Intolerance in Renal Failure
COMPLETED · Phase 2
-
International (Pediatric) Peritoneal Biobank
RECRUITING
-
Empagliflozin in ESKD - A Feasibility Study
RECRUITING · Phase 1
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.